<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548560</url>
  </required_header>
  <id_info>
    <org_study_id>FAME 02</org_study_id>
    <nct_id>NCT01548560</nct_id>
    <nct_alias>NCT01662245</nct_alias>
  </id_info>
  <brief_title>Assessing the Safety of Dapivirine Gel and Film Formulations</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <brief_summary>
    <textblock>
      This is a study to determine the safety of dapivirine gel and dapvirine film for healthy,
      HIV-uninfected women aged 18-45 years using the product for 7 daily doses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Grade 2 or higher Adverse Events</measure>
    <time_frame>5-11 weeks</time_frame>
    <description>The safety/toxicity endpoint is clinical or laboratory evidence of a Grade 2 or higher Adverse Event as defined by the DAIDS Table for Grading Adult and Pediatric Adverse Events, Version 1.0, December 2004 and the Female Genital Grading Table for Use in Microbicide Studies which is judged to be related to study product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in vaginal flora and vaginal pH</measure>
    <time_frame>5-11 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic and local absorption levels of dapivirine</measure>
    <time_frame>5-11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Dapivirine Vaginal Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapvirine Vaginal Film</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Film</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Film</intervention_name>
    <description>Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses</description>
    <arm_group_label>Dapivirine Vaginal Gel</arm_group_label>
    <arm_group_label>Dapvirine Vaginal Film</arm_group_label>
    <arm_group_label>Vaginal Film</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapivirine Vaginal Gel</intervention_name>
    <description>Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses</description>
    <arm_group_label>Dapivirine Vaginal Gel</arm_group_label>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_label>Dapvirine Vaginal Film</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 through 45 years (inclusive) at screening

          -  Able and willing to provide written informed consent to be screened for and to take
             part in the study.

          -  Able and willing to provide adequate locator information

          -  HIV-uninfected based on testing performed by study staff at screening (per algorithm
             in Appendices I)

          -  Per participant report, using an effective method of contraception at enrollment;
             hormonal method (except vaginal ring) used continuously for the past 30 days;
             intrauterine device (IUD inserted at least 30 days prior to enrollment); female
             sterilization; abstinent from sexual activity with male partner for the past 30 days;
             or sexual activity with vasectomized partner; and willingness to use effective method
             of contraception until the completion of final scheduled study visit if enrolled
             (approximately 35 days after enrollment)

          -  In general good health as determined by the site clinician

          -  For participants older than 21, a pap result in the 12 calendar months prior to
             Enrollment consistent with Grade 0 according to the Female Genital Grading Table for
             Use in Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and
             Pediatric Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009)
             or satisfactory evaluation with no treatment required of non-Grade 0 Pap result per
             American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines or per local
             standard of care, in the 12 calendar months prior to the Enrollment

        Note: For participants aged 18-21, a Grade-0 or adequately evaluated abnormal Pap smear is
        not required as the American Society for Colposcopy and Cervical Pathology recommends
        initiating screening at age 21.

          -  Agree to be sexually abstinent from Visit 1 until the completion of Visit 3

          -  Agree to use study condoms between Visits 3 and 4 (if heterosexually active)

          -  Agree to abstain from any other intravaginal product or penetration (including sex
             toys, excluding tampons) until Visit 3

          -  Willingness to undergo all study-related assessments and follow all study-related
             procedures

          -  At screening and enrollment, agrees not to participate in other research studies
             involving drugs, medical devices, or vaginal products while enrolled in this trial

        Exclusion Criteria:

          -  Menopause (as defined as amenorrhea for one year or more without an alternative
             etiology)

          -  Hysterectomy

          -  Participant report of any of the following:

               -  Known adverse reaction to any of the study products (ever)

               -  Known adverse reaction to latex (ever)

               -  Non- therapeutic injection drug use in the 12 months prior to Screening

               -  Surgical procedure involving the pelvis in the 90 days prior to enrollment
                  (includes dilation and curettage or evacuation, and cryosurgery; does not include
                  cervical biopsy for evaluation of an abnormal pap smear)

               -  Participation in a drug, spermicide and/or microbicide study in the 30 days prior
                  to enrollment or anticipated participation in an investigational drug study in
                  the next 8 weeks

               -  Pregnancy within 90 days of enrollment

               -  Currently lactating

               -  Use of a diaphragm, NuvaRingÂ®, or spermicide for contraception

               -  Internal vaginal use of any device or product (except tampons) in the 7 days
                  prior to enrollment

          -  Urogenital infection or suspected infection within 14 days of enrollment including:
             symptomatic candidiasis, trichomonas vaginalis, and symptomatic bacterial vaginosis;
             or cervical infection, including N. gonorrhea, C. trachomatis, or mucopurulent
             cervicitis; syphilis; HSV lesions, or other sores (Note: seropositive HSV without
             active lesions will not be excluded); acute pelvic inflammatory disease; urinary tract
             infection; recent exposure to a partner with GC, CT, Trichomonas, syphilis, or NGU

          -  Antibiotic or antifungal therapy (vaginal or systemic) within 7 days of enrollment

          -  As determined by the PI, has any significant uncontrolled active or chronic
             cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric,
             endocrine, respiratory, immunologic disorder or infectious disease

          -  Menses or other vaginal bleeding at the time of the Enrollment visit

          -  Has any of the following laboratory abnormalities per the Division of AIDS Table for
             Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 December 2004:

               -  Grade 1 or higher AST or ALT

               -  Grade 1 or higher creatinine

               -  Grade 2 or higher hemoglobin

               -  Grade 1 or higher platelets (Note: otherwise eligible participants with an
                  exclusionary test may be re-tested during the screening process).

          -  Any condition that, in the opinion of the Investigator, would preclude provision of
             consent, make participation in the study unsafe, complicate interpretation of study
             outcome data, or otherwise interfere with achieving the study objectives
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Bunge, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Magee Womens Hospital, UPitt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>Anti-HIV agents</keyword>
  <keyword>HIV-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

